Protein misfolding in neurodegenerative diseases: implications and strategiesPatrick Sweeney, Robert A. Hodgson, John Dunlop et al.|Translational Neurodegeneration|2017Cited by 671
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, Larry Ereshefsky et al.|Science Translational Medicine|2016Cited by 416
The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profilesGeoffrey B. Varty, Rosalia Bertorelli, Angelo Reggiani et al.|Psychopharmacology|2005Cited by 166
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s DiseaseJack D. Scott, Andrew W. Stamford, Mark S. Forman et al.|Journal of Medicinal Chemistry|2016Cited by 165
Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and DepressionRobert A. Hodgson, John C. Hunter, Angelo Reggiani et al.|Journal of Pharmacology and Experimental Therapeutics|2009Cited by 149